Black Ginger for Exercise Performance and Muscle: What the Trial Actually Found
Black ginger is sold hard into the sports-supplement aisle: "energy," "stamina," "endurance," a rhizome Thai labourers supposedly chewed before a day of heavy work. That framing rests on a small number of human trials: two randomised, placebo-controlled trials at Thai sports schools (2015 and 2020) and a 2010 study of a single dose that found no effect. The 2015 trial is a real, properly randomised trial, run at a sports school on actual athletes — which makes it worth reading closely rather than citing from the abstract. Read closely, it does not say what the marketing says it says.
Table of Contents
- What Is Actually Being Claimed
- The Soccer-Player Trial, Read in Full
- Six Tests, Three Time Points: Why One Hit Is Expected by Chance
- Grip Strength Is a Real Measurement — Just Not of This
- The Mouse and Cell Evidence: AMP-Activated Protein Kinase, Mitochondria and Inflammation
- A More Specific Finding: Aged Muscle, Not Athletic Muscle
- How Far an Oral Capsule Reaches: Blood, Not Yet Muscle
- Real Ergogenic Aids, for Comparison
- Numbers This Page Refuses to Give
- Evidence Ledger for This Claim
- Practical Bottom Line
- Key Research Papers
- Connections
- Featured Videos
What Is Actually Being Claimed
Supplement copy for black ginger tends to blur three separate claims into one confident paragraph. They need different evidence and have received very different amounts of it.
- Improves measurable athletic performance — strength, speed, agility, cardiorespiratory fitness in a trained athlete. This is the claim with actual randomised human trials behind it, covered in detail below.
- Increases general energy and reduces fatigue — the vaguer, older traditional framing, essentially untestable as stated and not addressed by any trial to date.
- Protects or rebuilds muscle tissue — the newest strand, built on rodent and cell-culture work on muscle inflammation, mitochondrial biogenesis, and age-related muscle loss (sarcopenia). Mechanistically interesting, entirely preclinical.
This page takes claim 1 first because it is the only one with real trials, then works backward through the mechanism claims that are used to explain it.
The Soccer-Player Trial, Read in Full
The trial is Promthep and colleagues, 2015, from Khon Kaen University: sixty soccer players at a sports school, randomised double-blind to 180 mg of standardised Kaempferia parviflora extract daily, or placebo, for 12 weeks. This is a genuinely good design for a supplement study — a real athlete population, real randomisation, real blinding, a chronic dose comparable to what a commercial capsule delivers.
Six fitness measures were tested at baseline and every four weeks: sit-and-reach flexibility, hand-grip strength, back-and-leg strength, a 40-yard technical dribbling test, a 50-metre sprint, and cardiorespiratory fitness. That is a sensible battery — it covers flexibility, strength, sport-specific skill, speed and endurance, which is close to everything a soccer player's fitness actually depends on.
Here is what the data showed, measure by measure, because this is the part that gets lost between the trial and the marketing:
- Right-hand grip strength — significantly higher than placebo at weeks 4, 8 and 12.
- Left-hand grip strength — significantly higher than placebo at week 8 only, not at weeks 4 or 12.
- Back-and-leg strength — no significant difference from placebo at any time point.
- 40-yard technical dribbling test — no significant difference from placebo at any time point.
- 50-metre sprint — no significant difference from placebo at any time point.
- Cardiorespiratory fitness — no significant difference from placebo at any time point.
One measure out of six moved, and it moved asymmetrically between two hands that share the same muscles and the same twelve weeks of training. The measure that moved is also, of the six, the one least connected to actually playing soccer — a sport that depends on leg power, sprint speed and ball skill, all three of which were flat. Read plainly, this is a largely negative trial with one isolated positive signal, not a demonstration that black ginger improves athletic performance. The paper's own abstract leads with the positive grip-strength finding, which is accurate reporting of what the study found, but it is also exactly the sentence that travels into marketing copy detached from the five negative results sitting next to it.
A second, larger trial, published in 2020, randomised 194 male students at a sports school, double-blind, to 360 mg a day of standardised extract or placebo for 12 weeks. Black ginger significantly increased right-hand grip strength, back-leg strength and maximal oxygen consumption (VO2 max) and shortened 50-metre sprint time, without changing the sit-and-reach flexibility test or the 40-yard technical test. Several heart-rate-variability measures also changed, and blood tests showed normal values in all participants.
A single dose did not help. In a 2010 report, two randomised, double-blind crossover studies in college men (19 and 16 men) gave black ginger or a starch placebo 90 minutes before exercise. There were no detectable differences in any measure across three all-out 30-second cycling sprints, and no effect on time to exhaustion, rating of perceived exertion or heart rate during steady cycling. The authors noted that the Mong hill tribe widely believe the herb reduces effort and improves work capacity and take it before their daily work, and that effects of long-term use could not be excluded.
Six Tests, Three Time Points: Why One Hit Is Expected by Chance
This is worth spelling out with the actual statistics, because "one significant result out of six" is not a curiosity — it is close to the base rate you would expect from testing six independent, uncorrelated measures at the conventional p<0.05 threshold, even if the treatment did nothing at all.
At a 5% significance threshold per test, the chance of at least one false positive across six independent tests is 1 − (0.95)6 ≈ 26% — roughly a one-in-four chance of seeing at least one "significant" result purely from multiple testing, before any real effect exists. The Promthep trial in fact ran six measures at three repeated time points, which inflates the number of comparisons further, and grip strength (right and left reported separately) effectively doubles the count again. None of this means the grip-strength finding is definitely noise. It means a single positive result out of many, unadjusted for multiple comparisons and not confirmed on the theoretically identical left-hand measurement at two of three time points, cannot be reported as "improves athletic performance" without materially overstating what was found. The methodological literature on this problem long predates this trial and is not specific to herbal research — it is the standard reason clinical trials pre-register a single primary endpoint rather than scoring everything and reporting whatever crossed the line.
Grip Strength Is a Real Measurement — Just Not of This
It is worth taking a detour on grip strength itself, because it is not a meaningless variable — it is one of the more validated simple measurements in medicine. Handgrip dynamometry is used worldwide as a proxy for overall muscular and physiological reserve, and the largest study of it, the Prospective Urban Rural Epidemiology (PURE) cohort of nearly 140,000 adults across 17 countries, found grip strength inversely associated with all-cause mortality: each 5 kg reduction in grip strength carried a hazard ratio of roughly 1.16 for death from any cause, and grip strength was a stronger predictor of death and cardiovascular events than systolic blood pressure.
That is a genuinely important number, and it is also precisely why it cannot be borrowed for an athletic-performance claim without comment. The PURE cohort measured grip strength as a marker of general physiological reserve in an ageing, largely untrained population — a proxy for sarcopenia, frailty and overall health. The Promthep cohort measured it in fit young soccer players already at the high end of the strength distribution, where the clinical meaning of a small grip-strength shift is not established at all. A validated mortality biomarker in one population is not automatically a validated performance biomarker in a completely different one; the instrument is the same, the inference it licenses is not.
The Mouse and Cell Evidence: AMP-Activated Protein Kinase, Mitochondria and Inflammation
The proposed mechanism behind an exercise-performance claim comes from Toda and colleagues, 2016, who gave mice black ginger extract orally for four weeks and then tested forced-swimming endurance. Treated mice swam longer, moved better immediately after swimming, and had greater grip strength than controls — alongside lower interleukin-6 (IL-6) and tumor necrosis factor-α messenger RNA in the soleus muscle (less inflammatory signalling), higher PGC-1α expression (more mitochondrial biogenesis signalling), more mitochondria, and more stored muscle glycogen. In cultured C2C12 muscle cells, the extract and its purified methoxyflavones activate AMP-activated protein kinase (AMPK), the cell's fuel-sensing enzyme that switches on when energy is scarce and pushes cells toward burning fuel and building mitochondrial capacity rather than storing fat.
That is a coherent story at the bench: less inflammation in the muscle, more mitochondrial machinery, more fuel on hand, translating into a mouse that swims longer. It is a cell-culture and mouse story. No human trial has measured muscle inflammation, mitochondrial density or muscle glycogen before and after black ginger supplementation. The Promthep trial measured performance outcomes in humans and mostly found nothing; the Toda work measured mechanism outcomes in mice and found a coherent signal. The two do not meet in the middle — there is no study connecting the mouse-level mechanism to the human-level results.
A More Specific Finding: Aged Muscle, Not Athletic Muscle
A separate and more specific 2020 study, by Kim and Hwang, deserves its own mention because it targets a different population entirely from the soccer trial, and the marketing rarely distinguishes the two. Working with purified 5,7-dimethoxyflavone (5,7-DMF) — black ginger's principal methoxyflavone, not a whole-extract preparation — the authors dosed 18-month-old mice (a genuine natural-ageing model, not young animals or a drug-induced atrophy model) orally at 25 or 50 mg/kg/day for eight weeks. They reported that 5,7-DMF favoured muscle protein synthesis over breakdown — activating the PI3K-Akt pathway that builds protein, while reducing expression of the E3 ubiquitin ligases and autophagy-lysosomal genes that break it down, via FoxO3 phosphorylation — and separately increased PGC-1α, NRF1 and TFAM (the core mitochondrial-biogenesis transcription programme) along with measurable increases in mitochondrial DNA content. At the whole-animal level, the authors reported that 5,7-DMF "not only stimulated grip strength and exercise endurance but also increased muscle mass and volume", and it lowered tumor necrosis factor-alpha and interleukin-6 levels in blood and muscle. In people, though, 5,7-DMF was not detected in the blood of healthy volunteers after 90 or 180 mg a day of black ginger extract (see the next section).
This is a more targeted and arguably more interesting finding than the soccer trial, because it is explicitly about age-related muscle loss (sarcopenia) rather than athletic performance in the young and fit — a different clinical question with a much larger unmet need and, at present, few good pharmacological options. It is also, again, aged mice only. Nobody has run the human equivalent: no trial has given 5,7-DMF or black ginger extract to older adults with low muscle mass and measured grip strength, gait speed, or lean mass by DEXA, the actual validated sarcopenia endpoints. Related preclinical work from the same compound family extends into diet-induced obesity models with a similar PGC-1α-mediated mitochondrial story, which strengthens the case that this is a real, reproducible laboratory signal — it does not shorten the distance to a human muscle-wasting trial that has not been run.
How Far an Oral Capsule Reaches: Blood, Not Yet Muscle
A mechanism finding is only as useful as the evidence that an oral human dose reaches the tissue where the mechanism was demonstrated. Sripanidkulchai and colleagues ran a pharmacokinetic study of standardised K. parviflora extract in healthy human subjects alongside an oral glucose tolerance test — useful groundwork showing that two of the methoxyflavones, pentamethoxyflavone and trimethoxyflavone, are absorbed and detectable in human blood after oral doses of 90 or 180 mg/day, while 5,7-dimethoxyflavone (5,7-DMF), the compound used in the sarcopenia study above, was not detected. At the 180 mg/day dose, pentamethoxyflavone peaked at 71.2 ng/mL and trimethoxyflavone at 63.0 ng/mL, at 4.02 and 6.03 hours, with half-lives of 2–3 hours; the same study found no effect of the extract on the oral glucose tolerance test. It is not, however, a muscle-tissue pharmacokinetic study; nobody has measured methoxyflavone concentration in human skeletal muscle after oral dosing, which is the actual site of both the mouse AMP-activated protein kinase-and-mitochondria mechanism and the sarcopenia finding above. This is the same gap that recurs across the whole black ginger literature: enzyme and cell-culture concentrations are demonstrated, blood absorption in humans is demonstrated, and the connecting step — concentration at the target tissue in a person who swallowed a normal capsule — is assumed rather than measured.
Real Ergogenic Aids, for Comparison
It is useful to know what a genuinely well-evidenced ergogenic aid looks like, so black ginger's file can be judged against a real standard rather than against silence. Caffeine has a large, repeatedly replicated meta-analytic literature showing measurable improvements in endurance, power and cognitive performance at doses of roughly 3–6 mg/kg, with dose-response data and mechanism (adenosine-receptor antagonism) worked out in detail. Creatine monohydrate has an even larger evidence base for strength, power output and lean-mass gains during resistance training, with decades of randomised trials, a well-characterised loading protocol, and one of the best safety records of any sports supplement. Both are inexpensive, over-the-counter, and dosed with actual precision because the dose-response relationship has been mapped.
Black ginger has no mapped dose-response relationship; its human performance file is two chronic-dose randomised trials (180 and 360 mg/day) and one single-dose crossover study. That does not make black ginger useless for other purposes — it makes it, on the performance claim specifically, a supplement with a small trial file standing where a much deeper literature exists for its established rivals.
Numbers This Page Refuses to Give
Several figures would make this page tidier and are not sourceable to anything that can be checked, so they are not given.
- A percentage improvement in strength or endurance. No trial reports an effect size that translates into a percentage a reader could expect. The one significant finding (grip strength) is reported as a group mean difference at specific weeks, not as a translatable percentage gain.
- A minimum effective dose. 180 mg/day and 360 mg/day are the two chronic human doses that have been tested for performance, in separate trials. Nobody has run a dose-ranging study, so there is no basis for a claim that more (or less) would work better.
- A time-to-effect. The one positive measure appeared at week 4 and was inconsistent at weeks 8 and 12 on the corresponding left-hand measurement, which is not a clean basis for stating how long supplementation should continue before an effect appears.
Evidence Ledger for This Claim
- Human athletic performance (the marketed claim). Tier: two randomised, double-blind, placebo-controlled trials with mixed results, plus one null single-dose study. In the 2015 trial (180 mg/day), five of six pre-specified measures showed no effect and the sixth (grip strength) was inconsistent between hands; in the 2020 trial (360 mg/day, 194 students), right-hand grip strength, back-leg strength, VO2 max and sprint time improved while flexibility and the technical test did not; a single dose 90 minutes before exercise had no effect. This is neither a clean negative nor a confirmed positive for the general performance claim.
- Muscle inflammation and mitochondrial biogenesis mechanism. Tier: consistent preclinical, cell-culture and mouse. Coherent AMPK/PGC-1α story, replicated across at least two research groups and two mouse models (exercise endurance, natural ageing). No human muscle-tissue data of any kind.
- Age-related muscle loss (sarcopenia). Tier: absent in humans. One well-designed aged-mouse study with real molecular detail; no human sarcopenia trial exists, and this is arguably the most promising untested application in the whole file.
- General "energy" and fatigue reduction. Tier: absent. Traditional claim, essentially untestable as commonly stated, no trial has targeted it directly.
Practical Bottom Line
- On measurable athletic performance, the human trials are mixed: the 2015 trial (180 mg/day) found an effect only on grip strength, the 2020 trial (360 mg/day) found better grip and back-leg strength, VO2 max and sprint time, and a single dose before exercise had no effect. Caffeine and creatine have much larger evidence bases for the same outcomes.
- On age-related muscle loss, the sarcopenia mechanism work is in aged mice only; no human trial exists yet. Resistance training and adequate dietary protein remain the interventions with actual human trial evidence for preserving muscle mass with age.
- On dose and safety, 180 mg/day and 360 mg/day of a standardised extract for 12 weeks are the doses with human outcome data, and blood tests stayed normal in all participants of the 360 mg/day trial; a 2017 systematic review of the clinical studies found no adverse events reported even when 1.35 g/day was used.
Key Research Papers
Each paper links to its PubMed record; the last four entries are PubMed topic searches.
- Promthep K, Eungpinichpong W, Sripanidkulchai B, Chatchawan U. Effect of Kaempferia parviflora extract on physical fitness of soccer players: a randomized double-blind placebo-controlled trial. Medical Science Monitor Basic Research, 2015. The central trial for this page; read past the abstract. PubMed PMID: 25957542
- Toda K, Hitoe S, Takeda S, Shimoda H. Black ginger extract increases physical fitness performance and muscular endurance by improving inflammation and energy metabolism. Heliyon, 2016. The mouse mechanism paper. PubMed PMID: 27441286
- Kim C, Hwang J-K. The 5,7-dimethoxyflavone suppresses sarcopenia by regulating protein turnover and mitochondria biogenesis-related pathways. Nutrients, 2020. Aged-mouse model; the most specific muscle mechanism paper in the file. PubMed PMID: 32295051
- Sripanidkulchai B, Mekjaruskul C, Areemit R, Cheawchanwattana A, et al. Glucose tolerance test and pharmacokinetic study of Kaempferia parviflora extract in healthy subjects. Nutrients, 2019. Confirms oral absorption of two methoxyflavones; does not measure muscle-tissue concentration. PubMed PMID: 31130666
- Chen D, Li H, Li W, Feng S, et al. Kaempferia parviflora and its methoxyflavones: chemistry and biological activities. Evidence-Based Complementary and Alternative Medicine, 2018. General chemistry and pharmacology reference. PubMed PMID: 30643531
- Saokaew S, Wilairat P, Raktanyakan P, Dilokthornsakul P, Dhippayom T, Kongkaew C, Sruamsiri R, Chuthaputti A, Chaiyakunapruk N. Clinical effects of Krachaidum (Kaempferia parviflora): a systematic review. Journal of Evidence-Based Complementary and Alternative Medicine, 2017. Independent overview of the whole clinical file. PubMed PMID: 27694558
- Leong DP and colleagues (Prospective Urban Rural Epidemiology study investigators). Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. The Lancet, 2015. Why grip strength matters — as a mortality marker in a different population than athletes. PubMed PMID: 25982160
- Sripanidkulchai B, Promthep K, Tuntiyasawasdikul S, Tabboon P, Areemit R. Supplementation of Kaempferia parviflora Extract Enhances Physical Fitness and Modulates Parameters of Heart Rate Variability in Adolescent Student-Athletes: A Randomized, Double-Blind, Placebo-Controlled Clinical Study. Journal of Dietary Supplements, 2022 (online 2020). The second, larger trial: 194 students, 360 mg/day. PubMed PMID: 33272042
- Wasuntarawat C, Pengnet S, Walaikavinan N, Kamkaew N, Bualoang T, Toskulkao C, McConell G. No effect of acute ingestion of Thai ginseng (Kaempferia parviflora) on sprint and endurance exercise performance in humans. Journal of Sports Sciences, 2010. The single-dose trials. PubMed PMID: 20845210
- The caffeine ergogenic-aid literature, for comparison. — Search PubMed
- The creatine ergogenic-aid literature, for comparison. — Search PubMed
- AMPK, skeletal muscle and exercise-induced mitochondrial biogenesis — the general mechanism literature behind the Toda and Kim findings. — Search PubMed
- The multiple-comparisons problem in randomized trials — the statistical background to the six-tests, one-hit finding above. — Search PubMed
External Resources
- NCCIH — how botanical evidence is graded.
- NIH Office of Dietary Supplements — supplement fact sheets and label literacy.
- PubMed — search the primary literature directly.
Connections
- All Herbs
- Black Ginger (Kaempferia parviflora) — the main topic page: botany, names, identification, traditional use, full cautions.
- Erectile Function and the PDE5 Claim — the other marketed claim, and the same "cell-culture story, thin human trial" pattern.
- Methoxyflavone Chemistry and Drug Interactions — the compounds behind the AMP-activated protein kinase mechanism, and why they also interact with prescription drugs.
- Metabolic Health, Blood Sugar and Brown Fat — the same AMP-activated protein kinase mechanism applied to a different clinical question.
- Creatine for Aging and Sarcopenia — a supplement with actual human sarcopenia trial evidence, unlike the mouse-only data here.
- Leucine for Sarcopenia Prevention — the amino-acid strand of the same muscle-preservation question, with human data.
- Metabolic Syndrome — where the AMP-activated protein kinase mechanism is more directly tested in humans, via metformin.
- Creatine — the ergogenic aid with the deepest human trial base, for direct comparison.
- Ginseng — another traditional "stamina" herb with a larger, if still mixed, human trial literature.
- Ashwagandha — a traditional adaptogen with genuine randomised strength and endurance trials.
- Kencur (Kaempferia galanga) — the same genus, a different rhizome, and a different chemistry entirely.
- Chen Pi (Aged Citrus Peel) — the other major dietary source of polymethoxyflavones.